Home›Clinical trials›Arizona

GLP-1 clinical trials in Arizona: 22 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

22 GLP-1 clinical trials are recruiting at 58 sites in 14 cities across Arizona. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Arizona

  1. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    10 sites in Arizona
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale. 602-386-4971
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler, Chandler. 480-443-8400
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff, Flagstaff. 928-666-3772
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Gilbert, Gilbert. 480-443-8400
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale, Glendale. 602-386-4969
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa, Mesa. 480-626-6637
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV, Phoenix. 480-626-6637
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City, Sun City. 602-386-4970
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson, Tucson. 520-867-6906
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast, Tucson. 520-849-8753

  2. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in Arizona

    • HonorHealth Research & Innovation Institute, Scottsdale. 480-323-1046

  3. Fibrosis Lessens After Metabolic Surgery

    Phase 4. Run by The Cleveland Clinic. Registry number NCT06374875.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (MASLD) with liver scarring (fibrosis), BMI 35+.

    1 site in Arizona

    • Banner Health Center, Phoenix

  4. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Arizona

  5. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    6 sites in Arizona
    • The Institute for Liver Health II dba Arizona Clinical Trials - Chandler, Chandler
    • Spectrum Research Institute, Gilbert
    • The Institute for Liver Health II dba Arizona Liver Health - Peoria, Peoria. 480-470-4000
    • Epic Medical Research-Sun City, Sun City
    • Del Sol Research Management, LLC, Tucson. 520-257-3881
    • The Institute for Liver Health II dba Arizona Clinical Trials - Tucson, Tucson

  6. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    5 sites in Arizona

  7. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    5 sites in Arizona

  8. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    4 sites in Arizona

    • Mission Research Institute - Gilbert, Gilbert. 833-602-2368
    • Helios Clinical Research - Paradise Valley, Paradise Valley. 833-602-2368
    • Arizona Liver Health - Peoria 85381, Peoria. 833-602-2368
    • Helios Clinical Research - Phoenix, Phoenix. 833-602-2368

  9. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    3 sites in Arizona

  10. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    3 sites in Arizona

    • Research Site, Mesa
    • Research Site, Phoenix
    • Research Site, Tempe

  11. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    2 sites in Arizona

  12. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Arizona

    • Kailera Clinical Site, Glendale
    • Kailera Clinical Site, Phoenix

  13. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Arizona

    • Elligo Health Research Inc, Gilbert
    • Velocity Clinical Research-Phoenix, Phoenix

  14. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Run by Amgen. Registry number NCT07575399.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    2 sites in Arizona

    • Arizona Clinical Trials, Chandler
    • Epic Medical Research - Sun City, Sun City

  15. Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

    Phase 3. Run by University of Chicago. Registry number NCT06499857.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with atrial fibrillation lose weight.

    Who can join. Adults 18 to 75, have obesity or are overweight, BMI 30+.

    1 site in Arizona

    • The University of Arizona College of Medicine- Phoenix, Phoenix. 602-521-3090

  16. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Arizona

    • University of Arizona, Tucson

  17. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    1 site in Arizona

    • Urologic Surgeons of Arizona, Mesa

  18. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    4 sites in Arizona

    • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
    • HOPE Research Institute, Phoenix
    • Headlands Research - Scottsdale, Scottsdale. 480-725-8708
    • The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson. 480-470-4000

  19. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in Arizona

  20. PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm

    Phase 2. Run by Veru Inc. Registry number NCT07446998.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with mobility disability lose weight.

    Who can join. Adults 65+, have obesity or are overweight, BMI 35+.

    1 site in Arizona

The other 2 studies recruiting in Arizona

  1. A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type

    Phase 2. Run by Antag Therapeutics. Registry number NCT07724340.

    A study testing whether an investigational medicine from Antag Therapeutics, AT673, can help people who are overweight lower blood sugar and lose weight.

    Who can join. Adults 18+, have type 2 diabetes, BMI 27+.

    1 site in Arizona

  2. Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight

    Phase 1. Run by Terrestrial Bio, Inc. Registry number NCT07673900.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

    Who can join. Adults 18 to 60, have obesity or are overweight, BMI 25+.

    1 site in Arizona

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.